



To: All Regional Medical Laboratory, Inc. (RML) Clients

From: Regional Medical Laboratory, Inc.
Sonya Bruening, BS, MLT (AMT), Manager of Immunology
Kevin W. Wamego BS, MLS,C(ASCP) Immunology Lead
Cindi Starkey, M.D., Laboratory Medical Director

Date: March 9, 2020

Subject: Kappa and Lambda Free Light Chain Testing

As part of Regional Medical Laboratory's and Pathology Laboratory Associates' ongoing efforts to ensure laboratory test offerings are in keeping with best practices, **we are announcing a change to our Kappa and Lambda Light Chain test offerings.**

Analysis of free kappa and free lambda light chains plays a vital role in the diagnosis, prognosis and ongoing monitoring of patients with a monoclonal gammopathy. It is imperative that free light chain results be interpreted alongside serum protein electrophoresis and/or immunofixation results in the context of the clinical presentation of the patient. Therefore, the previously offered **serum free light chain analysis with pathologist interpretation will NO longer be offered in the absence of an order for serum protein electrophoresis and/or immunofixation.** Serum free light chain analysis will continue to be offered as a stand-alone test, and numerical results will be reported, but it will no longer include a pathologist interpretation. This change will take place March 15, 2020.

RML will continue to offer Serum Protein Electrophoresis Analyzer testing for comprehensive evaluation as well as stand-alone protein electrophoresis, immunofixation and free light chain testing for a la carte ordering, if preferred. Please **review** the following **table** for a full list of RML's test offerings: